Latest Cancer treatments Stories
Cancers are notorious for secreting chemicals that confuse the immune system and thwarting biological defenses. To counter that effect, some cancer treatments try to neutralize the cancer's chemical arsenal and boost a patient's immune response--though attempts to do both at the same time are rarely successful. Now, researchers have developed a novel system to simultaneously deliver a sustained dose of both an immune-system booster and a chemical to counter the cancer's secretions,...
SUNNYVALE, Calif., July 16, 2012 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today that they have signed a definitive agreement to acquire Morphormics, Inc., a privately held company founded by University of North Carolina at Chapel Hill faculty members based on their research in autosegmentation of medical images. Morphormics develops medical imaging software systems that automatically recognize and extract anatomical...
SYDNEY, July 16, 2012 /PRNewswire/ -- An 82-year-old prostate cancer patient has become the first person in Australia to be treated using the fast and precise TrueBeam(TM) radiotherapy treatment system from Varian Medical Systems (NYSE:VAR). In a treatment carried out at the Crown Princess Mary Cancer Centre Westmead in Sydney, the patient received intensity modulated radiotherapy using the newly-installed system. The patient was also invited to unveil a plaque to mark the arrival...
CARACAS, Venezuela, July 12, 2012 /PRNewswire/ -- GURVE Radiation Oncology Group (Radioterapia Oncológica GURVE) in Caracas, Venezuela has become the first treatment center in the country to offer cancer patients RapidArc(TM) radiotherapy from Varian Medical Systems (NYSE: VAR). GURVE, which operates three cancer treatment centers in Venezuela, has treated more than 100 patients to date with RapidArc, a fast, accurate image-guided treatment that precisely targets tumors while...
CLEVELAND, July 11, 2012 /PRNewswire/ -- Investigators at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, have begun studying the imaging capabilities of an innovative radiation therapy system from ViewRay(TM) Incorporated. The ViewRay system is the first comprehensive image-guided radiation therapy system, providing a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance...
GULF SHORES, Ala., July 11, 2012 /PRNewswire/ -- Many patients find that after receiving image-guided cancer ablation, their bodies experience an anti-cancer immune response in which their immune system attacks untreated live tumors. Dr. Jason R. Williams of the American Cancer Ablation Center and Precision Imaging (http://www.cancerablation.com) is taking measures to enhance this response by combining the body's natural reaction to an ablated tumor with injections of...
SAN DIEGO, July 11, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB:ONCS), a company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, announces it has established the University of California San Francisco (UCSF) as the second enrolling site for its Phase II Merkel cell carcinoma clinical trial (OMS-I110). UCSF investigators are actively recruiting patients for this clinical trial. OMS-I110 was initiated at the University...
TSX Venture: QPT EDMONTON, July 10, 2012 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has hosted and completed a clinical investigators meeting in Rome, Italy with all of the Italian investigators participating in the ongoing, international Phase II oregovomab clinical trial for advanced ovarian cancer patients. The clinical meeting...
DALLAS, July 9, 2012 /PRNewswire-USNewswire/ -- UT Southwestern Medical Center, seeking to broaden an already robust array of radiation oncology treatments it offers to patients, potentially could play a key role in operating a state-of-the-art proton therapy center for North Texas being planned and funded by San Diego-based Advanced Particle Therapy (APT). The plan, announced today, is subject to the approval of the UT System Board of Regents. Under the terms of a letter of intent,...
BETHLEHEM, Pa., July 9, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today the company has achieved CE mark registration for its MyPaclitaxel(TM) and MyDocetaxel(TM) therapeutic dose management (TDM) MyCare(TM) assays, enabling commercialization in the European Union (EU). Saladax's MyCare technology...
